Difference between revisions of "Part:BBa K4165152"

 
Line 5: Line 5:
 
Tau binding peptide targeting the PHF seed of Tau
 
Tau binding peptide targeting the PHF seed of Tau
  
−
<!-- Add more about the biology of this part here
+
 
 
===Usage and Biology===
 
===Usage and Biology===
 +
 +
ISAD1 peptide with amino acid sequence of SVFKLSLTDAAS. It acts as an inhibitor for wild type full length tau aggregation. 
  
 
<!-- -->
 
<!-- -->
Line 12: Line 14:
 
<partinfo>BBa_K4165152 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165152 SequenceAndFeatures</partinfo>
  
 +
===Dry Lab===
 +
 +
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 +
 +
ISAL1 is modeled by AlphaFold2, Apptest, ITASSER, best model obtained from Apptest.
 +
 +
 +
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/isad1.png" style="margin-left:200px;" alt="" width="300" /></p>
 +
</html>
 +
 +
                            Figure 1.: Predicted 3D structure of Synthetic peptide ISAD1.
 +
 +
 +
 +
<p style=" font-weight: bold; font-size:13px;"> Table 1: Quality assessment parameters of ISAD1 model. </p>
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/isal1-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 +
</html>
 +
 +
 +
===References===
 +
1. Aillaud, I., Kaniyappan, S., Chandupatla, R. R., Ramirez, L. M., Alkhashrom, S., Eichler, J., ... & Funke, S. A. (2022). A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro. Alzheimer's research & therapy, 14(1), 1-19.
  
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  

Revision as of 18:04, 5 October 2022


ISAD1 Peptide

Tau binding peptide targeting the PHF seed of Tau


Usage and Biology

ISAD1 peptide with amino acid sequence of SVFKLSLTDAAS. It acts as an inhibitor for wild type full length tau aggregation.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

ISAL1 is modeled by AlphaFold2, Apptest, ITASSER, best model obtained from Apptest. 



                            Figure 1.: Predicted 3D structure of Synthetic peptide ISAD1.


Table 1: Quality assessment parameters of ISAD1 model.


References

1. Aillaud, I., Kaniyappan, S., Chandupatla, R. R., Ramirez, L. M., Alkhashrom, S., Eichler, J., ... & Funke, S. A. (2022). A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro. Alzheimer's research & therapy, 14(1), 1-19.